Patent SG-11201811003P-A (SG)
Title: Anti-pd-l1 antibodies and uses thereof
Inventor: FANG LEI
IPC: A61K39/395
Filed: 2017-06-13
Abstract: INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 21 December 2017 (21.12.2017) WIPO I PCT 0111111010 0111 inn Holonnimoilowommill (10) International Publication Number WO 2017/215590 Al (51) International Patent Classification: C07K 16/28 (2006.01) A61P 31/14 (2006.01) C07K 16/46 (2006.01) A61P 31/18 (2006.01) C12N 15/13 (2006.01) A61P 31/20 (2006.01) A61K 39/395 (2006.01) G01N 33/577 (2006.01) A61P 35/00 (2006.01) G01N 33/68 (2006.01) A61P 35/02 (2006.01) (21) International Application Number: PCT/CN2017/088033 (22) International Filing Date: 13 June 2017 (13.06.2017) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 201610414226.5 13 June 2016 (13.06.2016) CN PCT/CN2017/072566 25 January 2017 (25.01.2017) CN GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Declarations under Rule 4.17: as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii)) as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii)) of inventorship (Rule 4.17(iv)) Published: — with international search report (Art. 21(3)) W O 20 17 / 2155 90 Al (71) Applicant: I-MAB [CN/CN]; Suite 219, Building 6, Cham- time Plaza, 2889 Jingke Road, Shanghai 201206 (CN). (72) Inventors: FANG, Lei; Suite 219, Building 6, Cham- time Plaza, 2889 Jingke Road, Shanghai 201206 (CN). WANG, Zhengyi; Suite 219, Building 6, Chamtime Plaza, 2889 Jingke Road, Shanghai 201206 (CN). GUO, Bingshi; Suite 219, Building 6, Chamtime Plaza, 2889 Jingke Road, Shanghai 201206 (CN). ZANG, Jingwu; Suite 219, Build- ing 6, Chamtime Plaza, 2889 Jingke Road, Shanghai 201206 (CN). (74) Agent: SHANGHAI BESHINING LAW OFFICE; 21st Floor SFECO Mansion 681 Xiaomuqiao Road, Shanghai 200032 (CN). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, (54) Title: ANTI-PD-L1 ANTIBODIES AND USES THEREOF (57) : Provided are anti-PD-L1 antibodies or fragments thereof. The antibodies or fragments thereof specifically bind to the immunoglobulin C domain of the PD-L1 protein. In various example, the antibodies or fragments thereof include a VH CDR1 of SEQ ID NO: 1, a VH CDR2 of SEQ ID NO: 2, a VH CDR3 of SEQ ID NO: 3, a VL CDR1 of SEQ ID NO: 4, a VL CDR2 of SEQ ID NO: 5, and a VL CDR3 of SEQ ID NO: 6, or variants of each thereof. Methods of using the antibodies or fragments thereof for treating and diagnosing diseases such as cancer and infectious diseases are also provided.